The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Strong topline growth driven by solid performance across key brands.
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
The product is bioequivalent and therapeutically equivalent to the reference listed drug
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Subscribe To Our Newsletter & Stay Updated
